At the 76th annual AASLD Liver Meeting®, Novo Nordisk presented new findings from a post hoc analysis of the ESSENCE phase 3 trial, highlighting the impact of semaglutide 2.4 mg…
My name is Danielle, and in 2021, I was diagnosed with Stage 3 MASH, a life-threatening liver disease. I consider myself lucky because I had no real symptoms; my MASH was…
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as fatty liver disease, affects about one in three adults worldwide and poses major health risks, not only for the liver but…
Your story has the power to educate, motivate, and make a real difference in the lives of others. We are looking for patients with Metabolic Dysfunction-Associated Steatohepatitis, or MASH –…
Your story has the power to educate, motivate, and make a real difference in the lives of others. We are looking for patients with Metabolic Dysfunction-Associated Steatohepatitis, or MASH –…
Your story has the power to educate, motivate, and make a real difference in the lives of others. We are looking for patients with Metabolic Dysfunction-Associated Steatohepatitis, or MASH -…
August 2025 was a landmark month for rare disease innovation, as the U.S. Food and Drug Administration (FDA) granted four historic approvals, each representing a first for their respective conditions,…
Acknowledgement: Patient Worthy is proud to share this article from our friends at the Fatty Liver Foundation. As a patient, what I really want to understand is how damaged is…
The U.S. Food and Drug Administration (FDA) reported the approval of semaglutide injections for metabolic dysfunction-associated steatohepatitis (MASH), marking a major milestone in the fight against this increasingly common and…
ACKNOWLEDGEMENT – Patient Worthy is honored to partner with The Fatty Liver Foundation to provide you with this article. The Fatty Liver Foundation aims to improve the diagnosis, treatment & support…
Madrigal Pharmaceuticals is making significant strides in its mission to address metabolic dysfunction-associated steatohepatitis (MASH), as the company’s lead drug, REZDIFFRA, edges closer to regulatory approval in the European Union.…
Madrigal Pharmaceuticals has recently captured significant attention in the race to treat metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). As the landscape of liver disease therapeutics evolves,…
The results released from the Phase III ESSENCE clinical trial, and recently published by Medical Xpress and in the NEJM, found that the drug semaglutide is effective in the treatment…
According to a press release from the US Food and Drug Administration (FDA), the agency has approved the medication resmetirom (marketed as Rezdiffra) as the first-ever treatment intended to treat…
Over the past few years, Akero Therapeutics has experienced high highs and low lows in its efforts to advance efruxifermin, an investigational drug for people living with metabolic dysfunction-associated steatohepatitis…
According to a story from Healio, encouraging results from a phase 2 trial could herald a new standard of treatment for metabolic dysfunction-associated steatohepatitis (MASH). The investigational therapy is called…
Metabolic dysfunction-associated steatohepatitis (MASH) unfortunately has no treatments to reverse the disease or its damage. MASH can be managed through weight loss, regular exercise, and blood sugar management. But identifying…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
